AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2407227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion with doxorubicin hydrochloride (Adriamycin) 30 mg every 24 hours for 3 days, followed by irradiation (30 or 35 Gy in 10 fractions or 46 Gy in 23 to 25 fractions)
Number of subjects: 60
Study 2407227 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 60
Study 6407638 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 100
Study 6407638 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 100
Study 31390637 — intervention group
Group type: COMPARATOR
Intervention: Adapted reference values using the LMS method after instrumental dead space reduction
Number of subjects: 40
Study 31390637 — intervention group
Group type: COMPARATOR
Intervention: Standard lung function equipment adaptation
Number of subjects: 40
Study 30410653 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacomechanical catheter-directed thrombolysis (PCDT)
Number of subjects: 0
Study 30410653 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 27966318 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin administration after EMR (Group B)
Number of subjects: 115
Study 27966318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime administration after EMR (Group C)
Number of subjects: 115
Study 27966318 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics treatment after EMR (Group A)
Number of subjects: 115
Study 27966318 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 115
Study 25730927 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Number of subjects: 92
Study 25730927 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency magnetic therapy
Number of subjects: 92
Study 23645068 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynocular
Number of subjects: 69
Study 23645068 — intervention group
Group type: COMPARATOR
Intervention: Standard colposcope
Number of subjects: 69
Study 23645068 — intervention group
Group type: COMPARATOR
Intervention: Pap smear
Number of subjects: 69
Study 23645068 — intervention group
Group type: COMPARATOR
Intervention: Biopsy
Number of subjects: 69
Study 20516755 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cognitive dysfunction assessment
Number of subjects: 0
Study 20516755 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative delirium monitoring
Number of subjects: 0
Study 20516755 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine cognitive function assessment
Number of subjects: 0
Study 19083689 — intervention group
Group type: EXPERIMENTAL
Intervention: MET with 30‐s post‐isometric stretch phase
Number of subjects: 40
Study 19083689 — intervention group
Group type: EXPERIMENTAL
Intervention: MET with 3‐s post‐isometric stretch phase
Number of subjects: 40
Study 19083689 — intervention group
Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 40
Study 15721091 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol therapy
Number of subjects: 2708
Study 15721091 — intervention group
Group type: COMPARATOR
Intervention: Suspected nonfatal MI cohort
Number of subjects: 2708
Study 15721091 — intervention group
Group type: COMPARATOR
Intervention: Control group (no suspected nonfatal MI)
Number of subjects: 2708
Study 12666516 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint consultations by general practitioners and rheumatologists
Number of subjects: 166
Study 12666516 — intervention group
Group type: COMPARATOR
Intervention: Regular referral to the Rheumatology outpatients' clinic
Number of subjects: 166
Study 10535346 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg mifepristone orally followed by gemeprost 1 mg vaginally 24 hours later
Number of subjects: 64
Study 10535346 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg mifepristone orally followed by gemeprost 1 mg vaginally 48 hours later
Number of subjects: 64
Study 8690200 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 24
Study 8690200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1654983 — intervention group
Group type: COMPARATOR
Intervention: As required (AR) chemotherapy
Number of subjects: 300
Study 1654983 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned chemotherapy
Number of subjects: 300
Study 1654983 — intervention group
Group type: COMPARATOR
Intervention: As required (AR) chemotherapy with treatment-free interval (TFI) greater than 8 weeks
Number of subjects: 300
Study 1654983 — intervention group
Group type: COMPARATOR
Intervention: As required (AR) chemotherapy with treatment-free interval (TFI) less than 4 weeks
Number of subjects: 300
Study 1654983 — intervention group
Group type: COMPARATOR
Intervention: Quality of life assessment for AR patients
Number of subjects: 300
Study 6896672 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecithin
Number of subjects: 0
Study 6896672 — intervention group
Group type: EXPERIMENTAL
Intervention: Safflower oil
Number of subjects: 0
Study 6896672 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic acid (from lecithin and safflower oil)
Number of subjects: 0
Study 6896672 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30775818 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic motor intervention (Ai Chi), 14 weeks
Number of subjects: 41
Study 30775818 — intervention group
Group type: COMPARATOR
Intervention: On-land motor intervention (Tai Chi), 14 weeks
Number of subjects: 41
Study 30235385 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel two-part skincare system (LVS)
Number of subjects: 0
Study 30235385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26598747 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib 600 mg orally twice daily
Number of subjects: 138
Study 24339179 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg at weeks 0, 2, and 4, followed by either CZP 200 mg every 2 weeks or CZP 400 mg every 4 weeks
Number of subjects: 409
Study 24339179 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 200 mg every 2 weeks or CZP 400 mg every 4 weeks
Number of subjects: 409
Study 24339179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study 22903484 — intervention group
Group type: EXPERIMENTAL
Intervention: Castor oil before imaging and fasting after midnight (group 1)
Number of subjects: 186
Study 22903484 — intervention group
Group type: COMPARATOR
Intervention: No bowel preparation and allowed to eat and drink before examination (group 2)
Number of subjects: 186
Study 19189371 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus best supportive care (BSC)
Number of subjects: 463
Study 19189371 — intervention group
Group type: COMPARATOR
Intervention: BSC alone
Number of subjects: 463
Study 19189371 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 463
Study 17264183 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D with calcium supplementation
Number of subjects: 45492
Study 17264183 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D alone
Number of subjects: 45492
Study 17264183 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D with calcium vs. Vitamin D alone
Number of subjects: 45492
Study 15260469 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory flow at 20 L/min
Number of subjects: 25
Study 15260469 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory flow at 60 L/min
Number of subjects: 25
Study 15260469 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant inspiratory flow
Number of subjects: 25
Study 15260469 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term comparative individual studies
Number of subjects: 25
Study 11584035 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice Stepping Reaction Time (CSRT) test
Number of subjects: 477
Study 11584035 — intervention group
Group type: EXPERIMENTAL
Intervention: CSRT test
Number of subjects: 477
Study 11584035 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests (Part B of the Trail Making Test)
Number of subjects: 477
Study 11584035 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps strength, simple reaction time, sway with eyes open on a compliant surface, and maximal balance range
Number of subjects: 477
Study 11584035 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual contrast sensitivity and lower limb proprioception
Number of subjects: 477
Study 9688295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP) in combination with ifosfamide (IFO) and vinorelbine (VNB)
Number of subjects: 20
Study 9688295 — intervention group
Group type: COMPARATOR
Intervention: Ifosfamide (IFO) and vinorelbine (VNB) plus G-CSF
Number of subjects: 20
Study 8075441 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% podophyllotoxin cream
Number of subjects: 80
Study 8075441 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% podophyllotoxin cream
Number of subjects: 80
Study 8075441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 2681015 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine ultrasound scanning
Number of subjects: 0
Study 2681015 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluative surveys
Number of subjects: 0
Study 782964 — intervention group
Group type: EXPERIMENTAL
Intervention: H3N2 vaccine
Number of subjects: 0
Study 782964 — intervention group
Group type: EXPERIMENTAL
Intervention: HEqN2 vaccine
Number of subjects: 0
Study 782964 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaccine (vaccine diluent)
Number of subjects: 0
Study 31970507 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteromedial OA (AMOA)
Number of subjects: 472
Study 31612398 — intervention group
Group type: EXPERIMENTAL
Intervention: USG II/IHN plus GFN block (Group G)
Number of subjects: 54
Study 31612398 — intervention group
Group type: COMPARATOR
Intervention: USG II/IHN block alone (Group I)
Number of subjects: 54
Study 28270128 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral templates for new referrals in four clinical areas (dyspepsia, suspected colorectal cancer, chest pain, confirmed or suspected chronic obstructive pulmonary disease)
Number of subjects: 500
Study 28270128 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral templates
Number of subjects: 500
Study 28270128 — intervention group
Group type: COMPARATOR
Intervention: Standard referral practice
Number of subjects: 500
Study 26577960 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional GIC with acid etching (Group CIE)
Number of subjects: 40
Study 26577960 — intervention group
Group type: COMPARATOR
Intervention: Conventional GIC without acid etching (Group CIN)
Number of subjects: 40
Study 26577960 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin modified GIC with acid etching (Group RMN)
Number of subjects: 40
Study 26577960 — intervention group
Group type: COMPARATOR
Intervention: Resin modified GIC without acid etching (Group RME)
Number of subjects: 40
Study 23811381 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic training
Number of subjects: 16
Study 23811381 — intervention group
Group type: COMPARATOR
Intervention: Robotic training
Number of subjects: 16
Study 23811381 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall skills improvement
Number of subjects: 16
Study 21257841 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic allograft
Number of subjects: 30
Study 21257841 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Weaver-Dunn
Number of subjects: 30
Study 21257841 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic suture
Number of subjects: 30
Study 21257841 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonanatomic allograft
Number of subjects: 30
Study 21257841 — intervention group
Group type: EXPERIMENTAL
Intervention: GraftRope
Number of subjects: 30
Study 21257841 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 19228800 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring (HT) - three strategies: (i) monthly telephone contact; (ii) monthly telephone contact plus weekly transmission of vital signs; (iii) strategy 2 plus monthly 24 h recording of cardiorespiratory activity
Number of subjects: 461
Study 19228800 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring (HT)
Number of subjects: 461
Study 19228800 — intervention group
Group type: COMPARATOR
Intervention: Usual outpatient care (control)
Number of subjects: 461
Study 15882713 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine double-J silicone ureteral stent (Group 1)
Number of subjects: 100
Study 15882713 — intervention group
Group type: COMPARATOR
Intervention: No stent (Group 2)
Number of subjects: 100
Study 15882713 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 14645935 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nicotine patches
Number of subjects: 0
Study 14645935 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 0
Study 14645935 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard counselling)
Number of subjects: 0
Study 14645935 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined patch groups (active + placebo)
Number of subjects: 0
Study 10847315 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 423
Study 10847315 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 423
Study 8774165 — intervention group
Group type: EXPERIMENTAL
Intervention: B mode ultrasonography in Takayasu's arteritis
Number of subjects: 16
Study 8774165 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 16
Study 1466869 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intrathecal baclofen infusion
Number of subjects: 10
Study 3882364 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (M)
Number of subjects: 72
Study 3882364 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (C)
Number of subjects: 72
Study 3882364 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole and Cotrimoxazole (C plus M)
Number of subjects: 72
Study 3882364 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 72
Study 31059495 — intervention group
Group type: EXPERIMENTAL
Intervention: Biannual mass drug administration (MDA) with praziquantel alone
Number of subjects: 22500
Study 29625469 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light stimulation (1.4, 7.1, 14.3, 28.6, 42.9, 57.1, 71.4 cd/m2)
Number of subjects: 11
Study 29625469 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular viewing
Number of subjects: 11
Study 29625469 — intervention group
Group type: COMPARATOR
Intervention: Red light stimulation (1.5, 19.1, 38.2, 57.3, 76.3, 152.7, 305.3 cd/m2)
Number of subjects: 11
Study 26633188 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV)
Number of subjects: 40
Study 26633188 — intervention group
Group type: COMPARATOR
Intervention: Synchronized Intermittent Mandatory Ventilation (SIMV)
Number of subjects: 40
Study 25035603 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga group (with standard medical treatment and yogic intervention)
Number of subjects: 241
Study 25035603 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard medical treatment without yogic intervention)
Number of subjects: 241
Study 22181063 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (iGlar) with regular insulin (iReg)
Number of subjects: 20
Study 22181063 — intervention group
Group type: COMPARATOR
Intervention: Standard intensive care unit protocol (St. Care)
Number of subjects: 20
Study 20837925 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 308
Study 20837925 — intervention group
Group type: COMPARATOR
Intervention: ONCAB
Number of subjects: 308
Study 18811109 — intervention group
Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 51
Study 18811109 — intervention group
Group type: COMPARATOR
Intervention: Butterfly laser epithelial keratomileusis (butterfly LASEK)
Number of subjects: 51
Study 12764986 — intervention group
Group type: EXPERIMENTAL
Intervention: Live Lactobacillus plantarum 299 (10^9 live bacteria) with oat fibre substrate, administered twice daily for 7 days.
Number of subjects: 45
Study 12764986 — intervention group
Group type: COMPARATOR
Intervention: Heat-killed Lactobacillus plantarum 299, administered twice daily for 7 days.
Number of subjects: 45
Study 12764986 — intervention group
Group type: EXPERIMENTAL
Intervention: Live Lactobacillus plantarum 299 (treatment group)
Number of subjects: 45
Study 12764986 — intervention group
Group type: COMPARATOR
Intervention: Heat-killed Lactobacillus plantarum 299 (control group)
Number of subjects: 45
Study 11070638 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief clinician advice plus a 15-minute motivational counseling session
Number of subjects: 514
Study 11070638 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 514
Study 10021717 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with 200 mg/kg of porcine surfactant
Number of subjects: 93
Study 10021717 — intervention group
Group type: COMPARATOR
Intervention: Routine assistance (control)
Number of subjects: 93
Study 8418402 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency endoscopic retrograde cholangiopancreatography (ERCP) followed by endoscopic papillotomy within 24 hours of admission
Number of subjects: 195
Study 8418402 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment and selective ERCP with or without endoscopic papillotomy
Number of subjects: 195
Study 8418402 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency ERCP with or without endoscopic papillotomy
Number of subjects: 195
Study 3020960 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Number of subjects: 0
Study 3020960 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium lactate
Number of subjects: 0
Study 3020960 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium gluconate
Number of subjects: 0
Study 3020960 — intervention group
Group type: COMPARATOR
Intervention: Orange juice (as carrier)
Number of subjects: 0
Study 3020960 — intervention group
Group type: COMPARATOR
Intervention: Milk (as carrier)
Number of subjects: 0
Study 31315446 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly telemedical consultations in addition to regular care
Number of subjects: 240
Study 31315446 — intervention group
Group type: COMPARATOR
Intervention: Regular care (waiting control group)
Number of subjects: 240
Study 31315446 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 240
Study 31315446 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-economic analysis
Number of subjects: 240
Study 29573247 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Vaccine (GC3110A)
Number of subjects: 528
Study 29573247 — intervention group
Group type: COMPARATOR
Intervention: Trivalent Influenza Vaccine (Control)
Number of subjects: 528
Study 27031953 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder stimulation technique
Number of subjects: 142
Study 24733354 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-to-consumer educational intervention
Number of subjects: 303
Study 24733354 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 303
Study 21596578 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (1.5 mg kg(‐1) via paravertebral subpleural catheter for 3 days)
Number of subjects: 45
Study 21596578 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.2 mg kg(‐1) via paravertebral subpleural catheter for 3 days)
Number of subjects: 45
Study 21596578 — intervention group
Group type: COMPARATOR
Intervention: Control (tramadol 100 mg plus metamizol 1000 mg intravenously every 4 h for 3 days)
Number of subjects: 45
Study 21596578 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 45
Study 21596578 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 45
Study 20438942 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 24
Study 20438942 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy +/- radiation therapy or surgery alone (historical controls)
Number of subjects: 24
Study 18641716 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol (PS) intervention
Number of subjects: 26
Study 18641716 — intervention group
Group type: COMPARATOR
Intervention: Control phase
Number of subjects: 26
Study 15810771 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole practice group (practiced all four components together)
Number of subjects: 0
Study 15810771 — intervention group
Group type: EXPERIMENTAL
Intervention: No Overlap group (practiced first two and last two components, alternating every fifth trial)
Number of subjects: 0
Study 15810771 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlap group (practiced transition between second and third components, alternating first three and last three components every five trials)
Number of subjects: 0
Study 12859465 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 67
Study 12859465 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 67
Study 12859465 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 67
Study 10100253 — intervention group
Group type: COMPARATOR
Intervention: brimonidine 0.2%
Number of subjects: 85
Study 10100253 — intervention group
Group type: EXPERIMENTAL
Intervention: apraclonidine 0.5%
Number of subjects: 85
Study 8724923 — intervention group
Group type: EXPERIMENTAL
Intervention: KR on every trial
Number of subjects: 51
Study 8724923 — intervention group
Group type: EXPERIMENTAL
Intervention: Summary KR
Number of subjects: 51
Study 8724923 — intervention group
Group type: EXPERIMENTAL
Intervention: Average KR
Number of subjects: 51
Study 8724923 — intervention group
Group type: COMPARATOR
Intervention: No KR
Number of subjects: 51
Study 1725148 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 400mg
Number of subjects: 123
Study 1725148 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 200mg
Number of subjects: 123